HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET.
Go here to read the rest:
Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference
Related Post
- Better Choice Company Board of Directors Authorize Stock Repurchase Program - August 18th, 2021
- Comment on news - August 18th, 2021
- Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine... - August 18th, 2021
- Greenrose Acquisition Corp. Increases Full Year 2022 Financial Outlook - August 18th, 2021
- 22nd Century to Present at SNN Network Investor Conference on August 19 - August 18th, 2021
- XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium - August 18th, 2021
- Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021 - August 18th, 2021
- Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion... - August 18th, 2021
- Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and... - August 18th, 2021
- Zivo Bioscience, Inc. Issues Letter to Shareholders - August 18th, 2021
- Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency - August 18th, 2021
- Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25 - August 18th, 2021
- FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors - August 18th, 2021
- ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units - August 18th, 2021
- Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer - August 18th, 2021
- Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results - August 18th, 2021
- Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Telix and Merck to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Two New Studies to Explore Telix Assets in Breast Cancer Theranostics - August 18th, 2021
- Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region - August 18th, 2021
- Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference - July 22nd, 2021
- Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 - July 22nd, 2021
- Ladenburg Thalmann to Host R&D; Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 - July 22nd, 2021
- LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare... - July 22nd, 2021
- Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom - July 22nd, 2021
- Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory... - July 22nd, 2021
- Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing - July 22nd, 2021
- Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board - July 22nd, 2021
- Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2... - July 22nd, 2021
- Spectral Medical Inc. Announces $10 Million Offering - July 22nd, 2021
- Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021 - July 22nd, 2021
- Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug... - July 22nd, 2021
- Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update - July 22nd, 2021
- ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients - July 22nd, 2021
- Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units - July 22nd, 2021
- Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities - July 22nd, 2021
- TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock - July 22nd, 2021
- TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million - July 22nd, 2021
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results - July 22nd, 2021
- argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 - July 22nd, 2021
- Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China - July 7th, 2021
- Praxis Precision Medicines to Present at Upcoming Investor Conferences - July 7th, 2021
- Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - July 7th, 2021
- Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum - July 7th, 2021
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology - July 7th, 2021
- CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors - July 7th, 2021
- Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations - July 7th, 2021
- ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM - July 7th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021 - July 7th, 2021
- Integrity Implants and Fusion Robotics Merge to Form Accelus - July 7th, 2021
- AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET - July 7th, 2021
- FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients - July 7th, 2021
- Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional... - July 7th, 2021
- Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel... - July 7th, 2021
- NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - July 7th, 2021
- Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative... - July 7th, 2021
- Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis - July 7th, 2021
- Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - July 7th, 2021
- XBiotech Announces Dividend to Holders of Common Stock - July 7th, 2021
- Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 - July 7th, 2021
- Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference - May 28th, 2021
- Kane Biotech Announces First Quarter 2021 Financial Results - May 28th, 2021
- OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®... - May 28th, 2021
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - May 28th, 2021
- Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights - May 28th, 2021
- Ascendis Pharma A/S Reports First Quarter 2021 Financial Results - May 28th, 2021
- Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress - May 28th, 2021
- Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the... - May 28th, 2021
- Vaxcyte to Present at the Jefferies Virtual Healthcare Conference - May 28th, 2021
- AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - May 28th, 2021
- GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 - May 28th, 2021
- Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology - May 28th, 2021
- LIDDS intends to carry out a directed share issue of approximately MSEK 45 - May 28th, 2021
- Immunocore to present at upcoming investor conferences - May 28th, 2021
- MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings - May 28th, 2021
- Travere Therapeutics to Present at Upcoming Investor Conferences - May 28th, 2021
- Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq - May 28th, 2021
- Iterum Therapeutics Provides Update on NDA Review - May 28th, 2021
- Medexus Announces Amendments to its Credit Agreements - May 28th, 2021
- The performance of Olainfarm Group in Q1 2021 is convincingly resilient - May 28th, 2021